Brain Cancer

Adilia Hormigo, MD, PhD, discusses the current treatment landscape of glioblastoma.

The investigational immunotherapeutic ERC1671 in combination with granulocyte-macrophage colony-stimulating factor, cyclophosphamide, and bevacizumab showed promising activity in patients with recurrent glioblastoma.

David A. Reardon, MD, discusses the design of a phase 1/2 trial with INO-5401 and INO-9012 in glioblastoma.

The FDA has granted a fast track designation to paxalisib for the treatment of patients with glioblastoma.

David A. Reardon, MD, discusses the role of INO-5401 and INO-9012 in glioblastoma.

The biologics license application for the investigational B7-H3–targeting monoclonal antibody omburtamab for use in pediatric patients with central nervous system/leptomeningeal metastases from neuroblastoma has been submitted to the FDA under the agency’s Rolling Review process.

The FDA has granted a fast track designation for the PKCβ inhibitor enzastaurin for the treatment of patients with newly diagnosed glioblastoma.

Efforts are underway to expedite the identification of therapies that offer promise for patients with glioblastoma

A biologics license application has been submitted to the FDA for omburtamab, previously referred to as burtomab, for the treatment of pediatric patients with central nervous system/leptomeningeal metastases from neuroblastoma.

The FDA has granted an orphan drug designation to berubicin for the treatment of patients with malignant gliomas.

The FDA has granted a priority review designation to a biologics license application for the investigational, humanized monoclonal antibody naxitamab (Danyelza) for the treatment of patients with relapsed/refractory high-risk neuroblastoma.

Investigators of the first global adaptive phase 2/3 GBM Adaptive Global Innovative Learning Environment platform trial are implementing a multiarm, 2-stage approach to concurrently evaluate single-agent and combination regimens in glioblastoma.

AV-GBM-1 showed early promise in an interim overall survival analysis of an ongoing phase II trial in patients with newly diagnosed glioblastoma.

Treatment with paxalisib, an investigational small molecule inhibitor of the PI3K/AKT/mTOR pathway, was associated with a positive overall survival signal in patients with glioblastoma.

A Biologics License Application has been filed with the FDA for naxitamab for the treatment of patients with relapsed/refractory high-risk neuroblastoma.

Connor Liu, medical student, Washington University School of Medicine, discusses the importance of combination immunotherapy in orthotopic murine glioblastoma.

Single-agent vorasidenib or ivosidenib led to brain penetrance and 2-hydroxyglutarate suppression in patients with low-grade glioma who harbor IDH1 mutations.

The combination of INO-5401 and INO-9012 with cemiplimab, plus chemoradiation, demonstrated promising 6-month progression-free survival rates in patients with newly diagnosed glioblastoma multiforme that is O6-methylguanine-DNA methyltransferase methylated or unmethylated.

Treatment with Toca 511 and Toca FC did not improve overall survival compared with standard therapy in patients with recurrent high-grade glioma undergoing resection, missing the primary endpoint of the phase III Toca 5 trial.

The combination of nivolumab plus standard temozolomide and radiation therapy did not show a statistically significant improvement in progression-free survival compared with temozolomide/radiation therapy alone in patients with newly diagnosed glioblastoma multiforme that is O6-methylguanine-DNA methyltransferase-methylated, missing one of the primary endpoints of the phase III CheckMate-548 trial.

Investigators at the University of Wisconsin American Family Children’s Hospital are developing a new approach to treating patients with neuroblastoma that has the potential to improve outcomes for patients whose disease has not responded to conventional therapy.

Priya U. Kumthekar, MD, assistant professor of neurology and medicine, Northwestern University Feinberg School of Medicine, discusses frontline therapy for patients with anaplastic astrocytoma.

Eric T. Wong, MD, associate professor of neurology at Harvard Medical School and co-director of the Brain Tumor Center at Beth Israel Deaconess Medical Center, discusses recent negative trials in glioblastoma.

David A. Reardon, MD, clinical director, Center for Neuro-Oncology, institute physician, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses the immunogenicity of glioblastoma.

Eflornithine (α-Difluoromethylornithine) has been investigated for over 30 years as a potential neuro-oncology agent and shown activity against recurrent gliomas, but it has not gained approval as a therapy option for patients with cancer. Investigators are looking to change that with the phase III STELLAR trial (NCT02796261).